VIVAVACS

• 72110 - Research and experimental development on biotechnology
• 72190 - Other research and experimental development on natural sciences and engineering
• 86900 - Other human health activities

Our unique approach is to combine our DNA with retinoic acid that also induces cell maturation and death. In addition to the acquired immune responses our strategy enhances pre-existing immune responses initiated by the tumour antigens. VivaVacs is seeking funds to conduct the human clinical trials and is looking for partners... VivaVacs aims to develop a DNA-based immunotherapy strategy to prevent cancer relapses. Target diseases include a broad range of haematological cancers - leukemia (acute and chronic) and solid tumours (breast and colon carcinomas), for which preclinical studies on mouse models have shown efficacy. This activating platform has also the potential for application in other cancers.

Also known as: VIVAVACS LIMITED

Registration numbers: 13178974 (CH)

Primary location: Cambridge United Kingdom